Articles about Russian Direct Investment Fund

The Serum Institute of India (SII) will begin producing the Russian COVID-19 vaccine, Sputnik V, from September, the Russian Direct Investment Fund (RDIF) announced today.

Morepen Laboratories has started production of the test batch of Russia's Sputnik V COVID-19 vaccine at its facility in Himachal Pradesh, the Russian Direct Investment Fund (RDIF) and the drug firm said in a statement on Tuesday.

Sputnik V, the Russia-made coronavirus vaccine, will be manufactured in India by five pharmaceutical firms. It is estimated that 850 million doses will be produced yearly.

Stelis Biopharma, the biopharmaceutical arm of Bengaluru-based Strides Pharma Science, will be making and supplying at least 200 million doses of the Sputnik V vaccine, the Russian coronavirus vaccine currently awaiting emergency use approval in India.

Developers of the Russian coronavirus vaccine Sputnik V on Monday announced signing an agreement with AstraZeneca to test a combination of the British drug maker's COVID-19 shots and a component of the vaccine created in Moscow.

India will reportedly produce around 300 million doses of the Russian COVID-19 vaccine called Sputnik V.

Russian President Vladimir Putin on Wednesday ordered authorities to start mass voluntary vaccinations for COVID-19.

India will produce over 100 million doses a year of the Russian COVID-19 vaccine Sputnik V starting 2021, under an agreement between the Russian Direct Investment Fund (RDIF) and Hyderabad-based Hetero Biopharma, Hindustan Times reported.

The Russian vaccine for COVID-19, called Sputnik V, has been found at least 91% effective in the second interim analysis.

Russia's COVID-19 vaccine candidate, called Sputnik V, is expected to start human trials in India soon.

Phase II clinical trials for the Russian COVID-19 vaccine, Sputnik V, will have 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General (DCGI) has told Sputnik.

India's drug regulator has refused to allow a large scale clinical trial of Russia's Sputnik V COVID-19 vaccine.

Sputnik V, the COVID-19 vaccine developed and approved by Russia, has shown side effects in some trial volunteers.

In a major development, Hyderabad-based pharma company Dr. Reddy's Laboratories has partnered with the Russian Direct Investment Fund (RDIF) to source their Sputnik V COVID-19 vaccine for India.

Russia has been in the headlines for its two-month-tested 'Sputnik V' COVID-19 vaccine.

Russian health officials are set to register a vaccine candidate for the novel coronavirus disease, COVID-19, as early as this week.